Bioheart Financial Statements
Bioheart Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
This data is provided as per license from EDGAR Online
Bioheart Income Statement
| 2007 | 2006 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.3 | 0.1 | 0.1 |
| Gross Profit ($ mil.) | 0.2 | 0.0 | -- |
| Operating Income ($ mil.) | (14.7) | (13.3) | -- |
| Total Net Income ($ mil.) | (18.1) | (13.2) | (13.2) |
| Diluted EPS (Net Income) | (1.37) | (0.69) | -- |
Bioheart Stock Quote & Chart
10/03/08 13:34:52 EST •
NASDAQ •
2.07
•
 0.0000
•
0.0000 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Bioheart Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 110.84 | 1.24 | 1.43 |
| Price/Earnings Ratio | -- | 19.33 | 14.88 |
| Price/Book Ratio | -- | 2.67 | 1.38 |
| Price/Cash Flow Ratio | -- | 13.08 | 8.89 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Bioheart Financial Ratios
Bioheart Competitive Intelligence
| Advanced Cell Technology | Baxter | MG Biotherapeutics | |
|---|---|---|---|
| Annual Sales ($ mil.) | 0.6 | 11,263.0 | 4.0 |
| Employees | -- | 46,000 | 50 |
| Market Cap ($ mil.) | -- | 39,986.5 | -- |
Competitive Landscape
